Praxis Precision Medicines, Inc. (PRAX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Core Insights - The main focus for the company is the Ulixa treatment for Essential Tremor, which is expected to be a significant driver for growth in the upcoming year [2] - The company has submitted New Drug Applications (NDA) for both Ulixa and Relutrigine, opting for a standard review process instead of a priority review to maintain a strong relationship with the FDA [2] Group 1 - The company anticipates a busy year ahead, primarily driven by the Ulixa treatment [2] - The decision to not request priority review for Ulixa was guided by factors aimed at strengthening the relationship with the FDA [2]